DiaMedica Therapeutics Inc

DMACNASDAQ · USD
9.36USD+0.32 (+3.54%)
1310

DiaMedica Therapeutics Inc (DMAC) Option Chain

Read more

Tracking the DMAC option chain helps you see every strike and expiry on DiaMedica Therapeutics Inc in one view, so you can quickly identify contracts that fit your thesis and your risk. It lays out bids, asks, volume, open interest, and Greeks across calls and puts, giving you the full map of DMAC options activity at a glance. Use our scanner to monitor the DMAC option chain in real time and filter for the trades that actually meet your criteria.

An option chain is the complete listing of all available option contracts on an underlying, organized by expiration date and strike price. For DMAC stock options, the chain shows call and put data side by side, making it easy to compare premiums, assess liquidity, and spot pricing dislocations. Reading it well means looking beyond the last price. Implied volatility by strike, volume to open interest ratios, and bid ask spreads all show where DMAC options are being actively traded, and where they are not.

DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. The company's lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase 2 REDUX trial for the treatment of patients with moderate or severe chronic kidney disease caused by Type I or Type II diabetes; and Phase 2/3 REMEDY2 trials for the treatment of patients with acute ischemic stroke. It is also developing DM300 that is in pre-clinical stage for the treatment of inflammatory diseases. The company was formerly known as DiaMedica Inc.

2026-11-20
5 strikes
Default
CALLsPUTs
Prob. OTM %Open InterestVolumeExtrinsic ValueIntrinsic ValueBidAskStrikeMoneyness %BidAskIntrinsic ValueExtrinsic ValueVolumeOpen InterestProb. OTM %
Loading option chain…

As of Nov 5, 2026

Stock Statistics

  • IndustryBiotechnology
  • SectorHealthcare
  • IV Rank3.97% Low
  • Market cap (M$)487
  • 52 weeks high-17.82%
  • 52 weeks low72.52%
  • Analyst recommendationStrong Buy
    1.00
  • Target price$15.50
    65.60% above the current stock price
  • Dividend—
  • Payout ratio—
  • Earnings date2026-11-11
  • P/E—
  • Future P/E—
  • EPS (ttm)-0.71
  • EPS growth next 5 years-9.82%

As of Nov 5, 2026